

Daniel M Halperin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3886592/publications.pdf>

Version: 2024-02-01

53
papers

3,910
citations

566801

15
h-index

168136

53
g-index

53
all docs

53
docs citations

53
times ranked

4415
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. <i>JAMA Oncology</i> , 2017, 3, 1335.	3.4	2,289
2	Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12351-12356.	3.3	574
3	Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. <i>Lancet Oncology</i> , The, 2017, 18, 525-534.	5.1	271
4	Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 695-703.	5.1	111
5	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 863-881.	0.5	88
6	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	1.6	52
7	Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. <i>Oncotarget</i> , 2017, 8, 99541-99551.	0.8	41
8	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. <i>Cancer Discovery</i> , 2021, 11, 2738-2747.	7.7	37
9	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 155-163.	0.9	34
10	Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. <i>Annals of Surgical Oncology</i> , 2018, 25, 1709-1715.	0.7	32
11	Management of Diarrhea in Patients With Carcinoid Syndrome. <i>Pancreas</i> , 2019, 48, 961-972.	0.5	31
12	A Tale of Two Tumors: Treating Pancreatic and Extrapancreatic Neuroendocrine Tumors. <i>Annual Review of Medicine</i> , 2015, 66, 1-16.	5.0	27
13	Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?. <i>Current Oncology Reports</i> , 2014, 16, 366.	1.8	26
14	Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2015, 22, 431-441.	1.6	26
15	Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. <i>Oncologist</i> , 2017, 22, 1451-1462.	1.9	20
16	A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. <i>BMC Cancer</i> , 2014, 14, 561.	1.1	15
17	Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. <i>BMC Cancer</i> , 2019, 19, 274.	1.1	15
18	Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. <i>Annals of Oncology</i> , 2017, 28, 1582-1589.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2022, 8, 904.	3.4	13
20	Management of Pancreatic Neuroendocrine Tumors. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 119-131.	1.0	11
21	Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. <i>Scientific Reports</i> , 2018, 8, 16863.	1.6	11
22	Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?. <i>Clinical Endocrinology</i> , 2017, 86, 791-797.	1.2	10
23	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. <i>Endocrine-Related Cancer</i> , 2020, 27, T9-T25.	1.6	10
24	Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 510-513.	0.5	9
25	Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 1123-1130.	0.5	9
26	Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 34-42.	1.2	9
27	A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4969-e4980.	1.8	9
28	SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2022, 29, 533-544.	1.6	9
29	Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome. <i>Medicine (United States)</i> , 2018, 97, e13390.	0.4	8
30	A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 381-386.	0.5	8
31	Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors. <i>Journal of Biomedical Optics</i> , 2020, 25, .	1.4	8
32	Direct costs of carcinoid syndrome diarrhea among adults in the United States. <i>World Journal of Gastroenterology</i> , 2019, 25, 6857-6865.	1.4	7
33	Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. <i>BMC Medical Research Methodology</i> , 2018, 18, 169.	1.4	6
34	Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. <i>Clinical Colorectal Cancer</i> , 2020, 19, e117-e123.	1.0	6
35	North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. <i>Pancreas</i> , 2020, 49, 723-728.	0.5	6
36	Operationalizing Virtual Trials in Oncology-From Aspiration to Action. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 953-957.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Whatâ€™s in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 265-267.	0.8	5
38	Management of adrenocorticotrophic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. <i>Surgery</i> , 2022, 172, 559-566.	1.0	5
39	Update on management of midgut neuroendocrine tumors. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 175-189.	0.4	4
40	Clinical Trial Design in Neuroendocrine Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 209-217.	0.9	4
41	Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 507-511.	0.7	4
42	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. <i>Neuroendocrinology</i> , 2021, 111, 850-862.	1.2	4
43	Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2131744.	2.8	4
44	Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2914-2919.	0.8	3
45	Future Directions in the Biology of Neuroendocrine Tumors. <i>Pancreas</i> , 2016, 45, 783-785.	0.5	3
46	[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. <i>Future Oncology</i> , 2016, 12, 313-321.	1.1	3
47	Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. <i>Journal of Surgical Research</i> , 2021, 268, 419-431.	0.8	3
48	Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e21006-e21006.	0.8	3
49	A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. <i>Pharmacoeconomics</i> , 2021, 39, 1271-1297.	1.7	2
50	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: History of the multiple endocrine neoplasia workshops and overview of MEN2019. <i>Endocrine-Related Cancer</i> , 2020, 27, E1-E5.	1.6	2
51	Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? â€™ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e300.	5.1	1
52	Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. <i>Annals of Surgical Oncology</i> , 2022, 29, 3072-3084.	0.7	1
53	Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. <i>Abdominal Radiology</i> , 2022, , 1.	1.0	1